This week, we are talking about the many benefits of melatonin, a final guidance issued by the US FDA, and the top 22 drug research firms! 1. US FDA is making sure that major disruptions in clinical trials are kept to a minimum. The final guidance that was issued discusses the transfer of review responsibility […]
This Week We’re Talking About: Clinical Trials Day, AstraZeneca update, and Hispanic Enrollment
It’s been a busy week so far in our industry! International Clinical Trials Day, an AstraZeneca update and we continue our discussion on the importance of diversity in Clinical Trials. 1. Did you know yesterday was International Clinical Trials Day? Do you know the meaning behind it? How did you celebrate? 2. IT’S JUST NOT GONNA HAPPEN! AstraZeneca […]
This Week We’re Talking About: Bone Marrow-on-a-Chip, QbD, and Marijuana
Big Pharma is still in the news, but we found some different topics to top our list of must-reads for the week! 1. A new tool for drug testing, “bone marrow-on-a-chip”, was found by Harvard scientists and it is hoped to provide a more accurate result than tests on animals. 2. QbD (quality by design) […]
This Week We’re Talking About: Pfizer, “I’m In”, & Cancer Drug
We discussed the “I’m In” program in our latest Blog article, Lack of Diversity in Clinical Trials, and it is in the news again! Other items of interest this week: Pfizer, AstraZeneca update and a Cancer Drug on hold. 1. More states are supporting the “I’m In” program, Virginia being the most recent! 2. AstraZeneca […]